m.Stock by Mirae AssetOpen Demat Account
m.Stock by Mirae Asset
Transgene Biotek Ltd logo

Transgene Biotek Ltd Share Price

Current price unavailable.
As on - | -
HealthcareSmall Cap

Volume Analysis

SPOT Pivot Levels

TypeClassicFibonacci
R1 --
R2--
R3--
PP- -
S1--
S2--
S3 --

Ratios

ParticularsDec 2025Sep 2025Jun 2025Mar 2025Dec 2024
ROCE--11.14--6.23-
ROE-19.41-8.93-
EPS-0.05-0.05-0.06-0.09-0.01

Peer Comparison

No data available
Scrip NamePriceDaily changeM CapPE Ratio1 Year Return

Corporate Action

April 13, 2026
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Transgene Biotek Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85195TG1990PLC011065</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>0</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: ANKITA JAIN <br/> Designation: COMPLIANCE OFFICER AND COMPANY SECRETARY <br/> EmailId: cs@transgenebiotek.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: PRASAD CHOWDARY <br/> Designation: CFO <br/> EmailId: accounts@transgenebiotek.com</div> </div> <div> <br/> Date: 13/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>

About Transgene Biotek Ltd

Equity img
Founded in March 1990 by Dr. Koteswara Rao, Transgene Biotek Limited was one of the first Biotechnology companies in India. Although Transgene began life manufacturing and selling diagnostic kits, it soon moved on to true biotech research, including the research and development of vaccines, oncology , New drug delivery technologies etc. The first major success came when it sold genetically enginee...
ISIN :INE773D01018

Registered Office

Plot No 69 & 70 IDA Bollaram

Contact number

-

Registrars

Big Share Services Pvt Ltd
3rd Flr 306 Rightwin Amrutha Ville Somajiguda Hyderabad-500082

Contact number

+ 91-40-23374967/23370

Management

K Koteswara Rao (Chairman)

K Koteswara Rao (Director)

Open IPO’s

View All

FAQs

The share price of Transgene Biotek Ltd on the BSE is - as on -